Notably, combination of CYH33 with another marketed CDK4/6 inhibitor abemaciclib also displayed synergistic effect against proliferation in 27 out of 33 ESCC PDC cells (Fig. 6d). Here, CDK4 is linked to esophageal squamous cell carcinoma.